THURSDAY, Sept. 24, 2020 (HealthDay News) — The ultimate phase of clinical trials for Johnson & Johnson’s coronavirus vaccine have started out, the corporation introduced Tuesday.
The Period three trials will consist of sixty,000 men and women and be the major for a coronavirus vaccine in the United States, The New York Times reported.
Johnson & Johnson’s ultimate-phase trials commenced months just after related trials of other coronavirus vaccines in the United States, but it may perhaps have some pros more than the other vaccines since it does not need to have to be stored in subzero temperatures and may perhaps call for just a person dose instead of two, according to specialists.
“It would be incredible if we had anything at a solitary dose,” since it could pace initiatives to curb the pandemic, Dr. Judith Feinberg, vice chairwoman for research in drugs at West Virginia College, advised the Times. She’s not concerned in the vaccine research.
Johnson & Johnson could know by the conclusion of the calendar year if the vaccine is secure and powerful, Dr. Paul Stoffels, the firm’s chief scientific officer, said at a information meeting on Tuesday, The Times reported.
Copyright © 2019 HealthDay. All rights reserved.